Now on
US Patent Office has issued a patent covering the use of trimethylangelicin in Cystic Fibrosis
The United States Patent and Trademark Office has issued on March 15th the US Patent number 9283206 covering the use of trimethylangelicin (TMA) as CFTR Corrector in Bronchial Epithelial Cells.
Rare Partners Charity Partner at SuisseGas Milano Marathon 2016.
Rare Partners Charity Partner at SuisseGas Milano Marathon 2016.
Run4Usher, #runandimagetofly with us for Usher Syndrome.
Orphan Drug Designation to Sirolimus
The European Commission grants Orphan Drug Designation to Sirolimus (Rapamycin) for the treatment of beta thalassaemia intermedia and major
Agreement between Rare Partners and Fondazione Telethon
Agreement between Rare Partners and Fondazione Telethon
#runandimagetofly with Alessandro and his fundraising campaign for Rare Partners
#runandimagetofly with Alessandro and his fundraising campaign for Rare Partners.
Class October, 2014. An article on Alessandro, one of the protagonists of Rare Partners' fundraising campaign at the 2014 Milan City Marathon.